Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Pharmaceutical

04/05/2026 13:11

May 4 (Reuters) - Takeda Pharmaceutical 4502.T said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage clinical trial.

 (Reporting by Sahil Pandey in Bengaluru; Editing by Shilpi Majumdar)

 ((Sahil.Pandey@thomsonreuters.com;))